Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Bioheart, Inc. (BHRT)

BHRT RSS Feed
Add BHRT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator InvestorStemCell, Gaintrader, HybridTrader, BioheartInc
Search This Board:
Last Post: 10/31/2014 10:41:40 PM - Followers: 159 - Board type: Free - Posts Today: 27

A COMMITMENT TO EXCELLENCE

Bioheart, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 

MyoCell 

MyoCell SDF-1 


MyoCath


AdipoCell

Bioheart’s lead product candidate is MyoCell®, a muscle stem cell therapy that is intended to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack.

MyoCell SDF-1 has received approval from the FDA to begin human clinical trials and is intended to be an improvement to MyoCell.

The MyoCath is a disposable needle injection catheter used for the delivery of biologic solutions to a targeted treatment site within the myocardium, the inner wall of the heart. 

Adipose (fat) tissue is readily available and has been shown to be rich in microvascular, myogenic and angiogenic cells.  Bioheart has recently applied to the FDA to begin trials using adipose derived stem cells or AdipoCell™ in patients with chronic ischemic cardiomyopathy.  

 


The Bioheart Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease.We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.

 

.

Management:

Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
 
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.
 

**Important: Mike Tomás' personal StemCellCEO blog!**
 

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.
 

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by Amazon.com, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame
 

 

Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Charles A. Hart  53 Director
Sam Ahn  59 Director
Kristen Comella  37 Director, Chief Scientific Officer
Sheldon T. Anderson 63 Director
     

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 
    
BHRT - Daily Candlesticks

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BHRT
Current Price
Volume:
Bid Ask Day's Range
Wiki
BHRT News: Small Company Offering and Sale of Securities Without Registration (d) 04:35 PM
BHRT News: Current Report Filing (8-k) 10/24/2014 04:46:28 PM
BHRT News: Amended Statement of Ownership (sc 13g/a) 10/15/2014 09:32:37 AM
BHRT News: Current Report Filing (8-k) 10/10/2014 04:00:53 PM
BHRT News: Amended Statement of Changes in Beneficial Ownership (4/a) 08/14/2014 01:01:15 PM
News News Alert: Small Company Offering and Sale of Securities Without Registration (d) 10/31/2014 04:35:33 PM
PostSubject
#11540  Sticky Note Bioheart, Inc. Completes Financing With Magna! HybridTrader 10/27/14 09:42:35 AM
#11517  Sticky Note Investing in Bioheart, Inc. $$$$$MUSTREAD$$$$ InvestorStemCell 10/26/14 05:19:10 PM
#6744  Sticky Note Bioheart Announces Positive 6 Month Data From Angel Gaintrader 04/03/14 05:59:37 PM
#11804   "Its great to see funders continue to pump Hopalongstocks 10/31/14 10:41:40 PM
#11803   Its great to see funders continue to pump HybridTrader 10/31/14 09:44:35 PM
#11802   Dubb, saw that- I'd probably hit click right Hopalongstocks 10/31/14 09:37:28 PM
#11801   Corrected myself already within 1 minute lol Gsdubb 10/31/14 09:31:14 PM
#11800   GREEN ON MONDAY IMO. andyshow 10/31/14 09:08:29 PM
#11799   "if the remaining 3mil were sold in no Hopalongstocks 10/31/14 09:08:03 PM
#11797   "Wow they sold all the shares at once?"??? Hopalongstocks 10/31/14 08:54:03 PM
#11796   No worries. But IMO I wouldn't be surprised andyshow 10/31/14 08:22:52 PM
#11795   Whoops read it wrong sorry :) Gsdubb 10/31/14 08:20:02 PM
#11794   Wow they sold all the shares at once? Gsdubb 10/31/14 08:18:34 PM
#11792   SEC Magna "credit line" registration statement "Form-D" looks Hopalongstocks 10/31/14 07:35:40 PM
#11791   http://ih.advfn.com/p.php?pid=nmona&article=64250378&xref=newsalert andyshow 10/31/14 07:27:45 PM
#11790   The volume has dropped way, way off now. Hopalongstocks 10/31/14 03:52:19 PM
#11789   Dubb, just as one more "interesting" point- look Hopalongstocks 10/31/14 12:54:36 PM
#11788   Thanks. I guess we'll see how it goes Gsdubb 10/31/14 11:32:03 AM
#11787   Dubb, I think one would be looking at Hopalongstocks 10/31/14 11:27:42 AM
#11786   I would think/hope that the SEC regulates and Investaholic33 10/31/14 11:02:13 AM
#11785   "Ways of a market maker" Hopalongstocks 10/31/14 11:02:01 AM
#11784   How is it trading? DieselJoe 10/31/14 10:52:23 AM
#11783   It is obvious there is manipulation going on HackThePlanet 10/31/14 10:50:26 AM
#11782   Interesting about "volume drying up" Gsdubb 10/31/14 10:41:30 AM
#11781   Very interesting. I just got off the phone Gsdubb 10/31/14 10:35:55 AM
#11780   "Ways of a market maker" grabbed this from andyshow 10/31/14 10:24:51 AM
#11779   Just some "service" that tries to hawk expensive Hopalongstocks 10/31/14 10:11:32 AM
#11778   http://www.digitaljournal.com/pr/2293676 Stem Cells Market - Global Industry An andyshow 10/31/14 02:27:43 AM
#11777   Although I am a long term investor of Gsdubb 10/30/14 06:21:16 PM
#11775   "Based on recorded statements Bioheart Inc has 1.28 Hopalongstocks 10/30/14 05:29:35 PM
#11774   If it wasn't for the 20%+ shorting daily Gsdubb 10/30/14 04:58:18 PM
#11773   From Macro-axis: Number of Shares Shorted is total amount Gsdubb 10/30/14 04:56:36 PM
#11772   Very simple it's called manipulation! Someone sold 300 Nano1 10/30/14 04:53:08 PM
#11770   Closed red, down 6%, on a day when Hopalongstocks 10/30/14 04:28:02 PM
#11769   Look at otcshortreport. There are days this week Gsdubb 10/30/14 04:07:19 PM
#11768   "The shorts are in a panic.." Hopalongstocks 10/30/14 04:00:35 PM
#11767   "I hope he does a good job, for Hopalongstocks 10/30/14 03:57:36 PM
#11766   I hope he does a good job, for ruke 10/30/14 03:38:48 PM
#11765   Saw this early this morning. Mike has an andyshow 10/30/14 03:35:27 PM
#11764   NEWS ruke 10/30/14 03:27:05 PM
#11763   Seminar on Regenerative Medicine Open to Public "Schmidt, who andyshow 10/30/14 03:15:30 PM
#11762   Biased nonsense-strongly disagree!! Ringohalfcan 10/30/14 02:29:16 PM
#11761   The shorts are in a panic... andyshow 10/30/14 01:44:03 PM
#11760   "We have an excellent CEO in command here." Hopalongstocks 10/30/14 01:00:50 PM
#11759   Yeah, there's some trades posting for sure now. Hopalongstocks 10/30/14 12:29:17 PM
#11758   I see 190,152 shares traded today @.0199 on JWMN 10/30/14 12:16:16 PM
#11757   Strongly disagree. IMO. Nano1 10/30/14 12:14:10 PM
#11756   Disagree HackThePlanet 10/30/14 12:09:16 PM
#11755   Agree HackThePlanet 10/30/14 12:02:54 PM
#11751   ONE HOUR into trading day, and it's flat-lined Hopalongstocks 10/30/14 10:54:59 AM
#11750   Man there is a lot of trades... DieselJoe 10/30/14 10:42:06 AM
#11749   "1st year is showing a ton of revenue. Hopalongstocks 10/30/14 10:39:42 AM
#11748   "Wrong those are already deferred in warrants through Hopalongstocks 10/30/14 10:24:20 AM
PostSubject